Study of the Effect of SR57667B on the Progression of Symptoms in Patients With Parkinson's Disease

Summary

The primary objective is to assess the effect of SR57667B at the dose of 4 mg/d on the progression of Parkinson symptoms in patients with early PD. The primary outcome will be the time to progression of disability warranting initiation of L-dopa or a dopamine agonist. Secondary outcomes will comprise assessments of symptoms, activities of daily living and global clinical status.

Timeline

Start

2003-07

Primary completion

2006-04

Completion

2006-04

Drugs

Indications